Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Inactivated COVID-19 Vaccine · 1 trial · 1 indication
Incidence of RT-PCR confirmed symptomatic COVID-19 cases with onset at least 14 days after the second dose
| Arm | Type | Description |
|---|---|---|
| Experimental Group | EXPERIMENTAL | subjects will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28. |
| Control Group | PLACEBO_COMPARATOR | subjects will receive two doses of placebo on day 0 and day 28. |
| Name | Type | Description |
|---|---|---|
| Inactivated COVID-19 Vaccine | BIOLOGICAL | The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection |
| Controlled vaccine | BIOLOGICAL | The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension. |
Inclusion Criteria: * Healthy children and adolescents aged 6 months to 17 years; * The participants and/or their guardians are able to understand and sign the informed consent voluntarily (in accordance with the local regulations); * Able to comply with study procedures based on the assessment of ...
Inactivated COVID-19 Vaccine is used for the prevention of COVID-19. It is an inactivated vaccine being developed by Sinovac Biotech, Ltd for use in children and adolescents. The vaccine is currently in Phase 3 clinical development and is considered investigational.
Inactivated COVID-19 Vaccine is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company listed on the stock exchange under the ticker SVA. The company is conducting clinical trials to evaluate the vaccine's efficacy, immunogenicity, and safety in pediatric and adolescent populations.
Inactivated COVID-19 Vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved for use. A Phase 3 trial has been completed to assess its efficacy, immunogenicity, and safety in children and adolescents.
Inactivated COVID-19 Vaccine has one completed Phase 3 clinical trial, identified as NCT04992260. This trial, titled 'Efficacy, Immunogenicity and Safety of COVID-19 Vaccine, Inactivated in Children and Adolescents,' enrolled 11,349 participants and was conducted in Chile, Malaysia, Philippines, and South Africa.
Inactivated COVID-19 Vaccine is an inactivated vaccine developed by Sinovac Biotech, Ltd. The company is known for its COVID-19 vaccine CoronaVac, which is also an inactivated vaccine. However, the specific name of the vaccine in this context is not provided, so it is not confirmed whether it is the same as CoronaVac.